about
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domainMultiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharidesInteraction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and sizeNon-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.Multispot, label-free biodetection at a phantom plastic-water interface.The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions.Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth.Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors.The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies.Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histoculturesHIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies.Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomavirusesSialic acid associated with αvβ3 integrin mediates HIV-1 Tat protein interaction and endothelial cell proangiogenic activation.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery.HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2.A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonistsSulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus.Role of the soluble pattern recognition receptor PTX3 in vascular biologyPolyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis.Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis.Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions.Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance.Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands.A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin.Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins.
P50
Q24300120-1F8ED39E-3CD9-499C-B234-3444ECB7F558Q28144903-C0A75EC1-0667-416C-8E90-0F568741F4CAQ28235546-F0BAD8F1-19E1-4BDF-B0F8-69D213FF575BQ30493655-CBF24928-9B6B-4BDE-A333-860E88C3965EQ30540513-48548EAC-54A3-4CB2-94F7-DFBC1A0D2373Q33213079-39A48F3B-7F4E-4EE9-9010-97C82FD7F700Q33602706-52F6738D-C15A-4B44-8970-AB906C439CFAQ33636333-038863B0-7B04-4923-A112-B8E9B2902E87Q34048021-128D0D8F-AFC5-4827-89E1-3E9DCAD50977Q34057989-107CA1E4-3B6A-47E1-8C55-921A397EA705Q34273824-B3912896-A176-490C-8397-330124E4BC0FQ34532772-49513379-EA63-4859-82C2-C409CD9CDEE2Q34632846-31AA9BDD-1A8D-4CEC-A0A9-2D1612E57315Q35014689-CD7F8C6D-A4F4-44AC-8C6D-FFBAFCA87D4BQ35164554-DA0E0C26-8F07-4707-B5C1-DEDF957970DEQ35634404-6B936E09-65F7-441C-A251-CB77F2E3DCE1Q35960675-15302862-1F86-40EB-8B19-25237B62E572Q36016939-1F87F0F7-3CFD-4A50-9B52-98BFC6CD3F51Q36111400-AB6B440F-FCB3-433D-B139-B7F0CAC0AF1FQ36198891-F683F4DC-DCFF-474C-801A-4B2DB3242D4DQ36221840-FBC6EBBC-91AB-4578-ACBE-777EDF8C99A7Q36389313-C690C3FF-7D66-4C18-AE90-E9973A486D5EQ36526260-FE881378-37E3-4704-8509-6A90AC8645CFQ36538770-07CEAB0B-5954-49BC-B41D-3142C222C791Q36924394-B2D8A902-7E67-4A4A-8220-6B85CAD3CCE9Q37323266-E48B018D-22BE-411B-93C4-DEFEA5AABDEFQ37597210-1BD0EED8-8A10-4AF3-8588-B1B147B49D40Q37622406-E435B63A-C7A2-4306-AD21-67F430794D60Q37997765-30E52401-96E9-46C5-9434-C9C646ACD5ECQ38141148-C788C185-1CF0-4B7B-AB29-622CA0ADD896Q38281376-1C0AB296-2AB8-40FF-B0EA-9BBA842EBCFCQ38363396-89061897-5556-4484-9F20-FD5358E1F82FQ38363705-118967A9-AA23-4B3F-85C5-AA92F774D1E8Q38418286-C6E00AF3-8099-45D5-90EA-55D13AB847A7Q38842676-65AAAF3B-4440-40C4-867F-9E0C83651188Q38907078-C3854765-C2BF-43BF-8604-E025C3DFD485Q38974266-038EDFD7-34EF-4350-9B18-5F07B6AC5353Q39304663-544C9BE2-6FA1-4472-8BC4-03D5FF901AC9Q39473169-EBECF4B0-9472-4D20-B312-C12EFDFFC0DDQ40142273-C51FB70D-9C0D-470C-8826-2594ED5AD254
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Rusnati
@ast
Marco Rusnati
@en
Marco Rusnati
@es
Marco Rusnati
@nl
type
label
Marco Rusnati
@ast
Marco Rusnati
@en
Marco Rusnati
@es
Marco Rusnati
@nl
altLabel
Marco RUSNATI
@en
prefLabel
Marco Rusnati
@ast
Marco Rusnati
@en
Marco Rusnati
@es
Marco Rusnati
@nl
P106
P1153
7003352380
P21
P31
P496
0000-0001-9968-5908